Contrasting Akari Therapeutics (NASDAQ:AKTX) and OKYO Pharma (NASDAQ:OKYO)

Akari Therapeutics (NASDAQ:AKTX) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Akari Therapeutics and OKYO Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akari Therapeutics	N/A	N/A	-$17.30 million	N/A	N/A
OKYO Pharma	N/A	N/A	-$8.95 million	N/A	N/A

Volatility and Risk

Akari Therapeutics has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Akari Therapeutics and OKYO Pharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akari Therapeutics	1	0	3	0	2.50
OKYO Pharma	1	1	3	0	2.40

Akari Therapeutics currently has a consensus target price of $32.33, suggesting a potential upside of 332.84%. OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 277.78%. Given Akari Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Akari Therapeutics is more favorable than OKYO Pharma.

Profitability

This table compares Akari Therapeutics and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Akari Therapeutics	N/A	-147.45%	-74.70%
OKYO Pharma	N/A	N/A	N/A

Institutional & Insider Ownership

5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 32.2% of Akari Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.